A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma
NCT00429949
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
21
Enrollment
OTHER
Sponsor class
Conditions
Relapsed, Refractory or Plateau Phase Multiple Myeloma
Interventions
DRUG:
Dasatinib
Sponsor
Washington University School of Medicine